hypericin has been researched along with evans blue in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bardine, C; Craik, CS; O'Donnell, HR; Shoichet, BK; Tummino, TA | 1 |
| Olivo, M; Soo, KC; Yee, KK | 1 |
2 other study(ies) available for hypericin and evans blue
| Article | Year |
|---|---|
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
Topics: Antiviral Agents; COVID-19 Drug Treatment; Drug Repositioning; Molecular Docking Simulation | 2021 |
Anti-angiogenic effects of Hypericin-photodynamic therapy in combination with Celebrex in the treatment of human nasopharyngeal carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Anthracenes; Celecoxib; Cyclooxygenase 2; Drug Therapy, Combination; Evans Blue; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Male; Mice; Mice, Inbred BALB C; Middle Aged; Nasopharyngeal Neoplasms; Necrosis; Neovascularization, Pathologic; Perylene; Photochemotherapy; Pyrazoles; RNA, Messenger; Sulfonamides; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2005 |